Stock SBTX SKINBIOTHERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials SkinBioTherapeutics plc

Equities

SBTX

GB00BF33H870

Biotechnology & Medical Research

Market Closed - London S.E.
Other stock markets
 11:35:08 2024-05-07 am EDT 		5-day change 1st Jan Change
9.25 GBX 0.00% Intraday chart for SkinBioTherapeutics plc +1.20% -39.34%
Apr. 05 SkinBioTherapeutics Gets Bond Conversion Notice from Macquarie MT
Mar. 22 SkinBioTherapeutics half-year revenue jumps on UK-based sales AN

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024
Capitalization 1 25.62 21.93 99.56 31.75 21.64 17.83
Enterprise Value (EV) 1 25.62 19.78 95.09 31.75 21.64 18.43
P/E ratio -21.3 x -14.6 x -64.8 x -12.6 x -7.27 x -6.17 x
Yield - - - - - -
Capitalization / Revenue - - - - - 16.2 x
EV / Revenue - - - - - 16.8 x
EV / EBITDA - -12.2 x -63.6 x - - -7.68 x
EV / FCF - - - - - -6.14 x
FCF Yield - - - - - -16.3%
Price to Book - - - - - 7.71 x
Nbr of stocks (in thousands) 128,083 128,083 156,780 156,780 173,139 192,796
Reference price 2 0.2000 0.1712 0.6350 0.2025 0.1250 0.0925
Announcement Date 11/26/19 12/4/20 11/30/21 12/15/22 11/30/23 -
1GBP in Million2GBP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024
Net sales 1 - - - - - 1.1
EBITDA 1 - -1.615 -1.495 - - -2.4
EBIT 1 - -1.62 -1.497 - - -2.5
Operating Margin - - - - - -227.27%
Earnings before Tax (EBT) 1 - -1.62 -1.498 - - -2.9
Net income 1 -1.148 -1.5 -1.433 -2.527 -2.835 -2.7
Net margin - - - - - -245.45%
EPS 2 -0.009400 -0.0117 -0.009800 -0.0161 -0.0172 -0.0150
Free Cash Flow 1 - - - - - -3
FCF margin - - - - - -272.73%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 11/26/19 12/4/20 11/30/21 12/15/22 11/30/23 -
1GBP in Million2GBP
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024
Net Debt 1 - - - - - 0.6
Net Cash position 1 - 2.16 4.47 - - -
Leverage (Debt/EBITDA) - - - - - -0.25 x
Free Cash Flow 1 - - - - - -3
ROE (net income / shareholders' equity) - - - - - -121%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - - - - - 0.0100
Cash Flow per Share - - - - - -
Capex 1 - - 0.11 - - 0.1
Capex / Sales - - - - - 9.09%
Announcement Date 11/26/19 12/4/20 11/30/21 12/15/22 11/30/23 -
1GBP in Million2GBP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SKINBIOTHERAPEUTICS PLC Stock SkinBioTherapeutics plc
-40.40% 22.42M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+9.15% 106B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.08% 104B
ARGENX SE Stock argenx SE
+6.99% 23.25B
BIONTECH SE Stock BioNTech SE
-11.55% 22.5B
GENMAB A/S Stock Genmab A/S
-7.26% 18.7B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.08% 17.95B
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.91% 16.99B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.55% 14.26B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+40.04% 12.76B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SBTX Stock
  4. Financials SkinBioTherapeutics plc
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW